Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,728.50
Bid: 1,727.00
Ask: 1,728.00
Change: 23.50 (1.38%)
Spread: 1.00 (0.058%)
Open: 1,705.00
High: 1,729.50
Low: 1,695.50
Prev. Close: 1,705.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London close: Stocks close lower on UK deflation, weak Chinese trade data

Tue, 13th Oct 2015 16:12

(ShareCast News) - The FTSE 100 ended down 28.90 points to 6,342.28 on Tuesday as September data showed the UK experienced deflation and China's exports and imports declined.The Office for National Statistics said the UK consumer price index fell 0.1% year-on-year last month, compared to analysts' estimates for a flat reading in line with August.On a month-on-month comparison, CPI also dropped 0.1% in September following a 0.2% increase in August. Analysts had predicted 0% growth.The main driver of deflation was discounting at clothing stores and falling petrol and diesel prices."As UK year-on-year inflation hit negative territory for only the second time since 1960, the impact of persistent disinflation upon Bank of England decision making will no doubt have been playing into traders mind-sets, sending GBP-USD 130 points lower within two hours," said IG market analyst Joshua Mahony."However, it is also worth bearing in mind that with wages growing at the fastest rate in over a decade, this is a benefit for the consumer and helps make up for all those years where real wages fell repeatedly."Chinese tradeChinese exports decreased 3.7% in September from a year earlier in US dollar terms following a 5.5% drop in August, the General Administration of Customs revealed. Analysts had expected a 6% slide.Imports plunged 20.4% last month, worse than the 15.9% dip predicted, after a 13.8% fall in August.The trade balance, however, unexpectedly widened to $60.34bn in September from $60.24bn a month earlier when a surplus of $47.90bn had been forecast."Chinese trade figures have been a source of concern for some time now, with both dollar-denominated exports and imports having contracted for most of the year when compared to 12 months previous," said Craig Erlam, senior market analyst at Oanda."The biggest concern is the huge decline in imports and while a large part of this can be attributed to the collapse in commodity prices and should therefore ease of in the coming months, there does also appear to be a domestic demand problem as well."McCafferty calls for rate riseBoE policymaker Ian McCafferty has reiterated that interest rates need to rise to allow more scope for cuts in the event of a financial crisis.In a testimony to the Treasury Committee on the hearing of McCafferty's reappointment to the Monetary Policy Committee on Tuesday, he said there was a need to return the Bank Rate far enough above zero "to a level at which it can be an effective instrument" in tightening or loosening policy. Last Thursday, McCafferty voted in favour of raising interest rates to 0.75% from 0.50%. He was once again the only policymaker to recommend the move.Royal Mail tops FTSE fallersRoyal Mail was in the red on news the government has sold its remaining stake in the postal service group to professional investors.Luxury fashion retailer Burberry was under the cosh amid renewed worries about China - to which it is heavily exposed - following disappointing trade figures.Barclays edged lower on reports the bank may name US investment banker Jes Stanley as its new chief executive.Going the other way, SABMiller jumped after the brewer agreed to a £68bn takeover offer from AB InBev.Housebuilders rallied in line with FTSE 250 peer Bellway which gained after posting a 44% jump in full-year profits that beat expectations. Persimmon, Barratt Developments and Taylor Wimpey were both firmly in the black.Pharmaceuticals giant GlaxoSmithKline was also on the front foot after JPMorgan Cazenove upgraded the stock to 'neutral' from 'underweight' and lifted the price target to 1,370p from 1,320p. The bank noted that medium-term consensus earnings per share estimates have fallen 15-18% year-to-date and expectations now look achievable, with downgrades no longer a concern. Market MoverstechMARK 3,034.34 -0.00%FTSE 100 6,341.41 -0.47%FTSE 250 16,902.78 -0.50% FTSE 100 - RisersSABMiller (SAB) 3,949.50p +9.06%GlaxoSmithKline (GSK) 1,328.50p +1.72%Persimmon (PSN) 1,967.00p +1.60%Carnival (CCL) 3,384.00p +1.50%Inmarsat (ISAT) 929.00p +1.42%Berkeley Group Holdings (The) (BKG) 3,250.00p +1.25%International Consolidated Airlines Group SA (CDI) (IAG) 577.00p +1.23%Barratt Developments (BDEV) 633.50p +1.20%easyJet (EZJ) 1,725.00p +1.17%Taylor Wimpey (TW.) 192.70p +1.05% FTSE 100 - FallersRoyal Mail (RMG) 453.30p -4.00%Tesco (TSCO) 194.30p -3.74%G4S (GFS) 248.20p -3.27%Burberry Group (BRBY) 1,427.00p -3.25%Aberdeen Asset Management (ADN) 333.80p -3.11%Standard Chartered (STAN) 739.40p -3.05%Johnson Matthey (JMAT) 2,520.00p -2.85%Sainsbury (J) (SBRY) 263.80p -2.73%Old Mutual (OML) 205.30p -2.61%Glencore (GLEN) 118.00p -2.60% FTSE 250 - RisersMichael Page International (MPI) 483.50p +4.16%Bellway (BWY) 2,453.00p +3.50%Spire Healthcare Group (SPI) 368.30p +3.40%Sophos Group (SOPH) 231.90p +3.25%Auto Trader Group (AUTO) 330.00p +2.96%Crest Nicholson Holdings (CRST) 540.50p +2.85%Virgin Money Holdings (UK) (VM.) 399.90p +2.51%BTG (BTG) 573.00p +2.32%CLS Holdings (CLI) 1,790.00p +2.11%Vectura Group (VEC) 165.10p +2.10% FTSE 250 - FallersKaz Minerals (KAZ) 135.40p -6.30%Evraz (EVR) 89.20p -5.56%Weir Group (WEIR) 1,284.00p -4.75%IMI (IMI) 1,012.00p -4.17%Vedanta Resources (VED) 578.50p -4.14%Rotork (ROR) 179.10p -3.92%Home Retail Group (HOME) 144.60p -3.73%Homeserve (HSV) 411.00p -3.54%Bodycote (BOY) 556.50p -3.30%Ashmore Group (ASHM) 282.50p -3.19% FTSE TechMARK - RisersNCC Group (NCC) 260.00p +4.00%Dialight (DIA) 664.00p +1.37%Oxford Biomedica (OXB) 7.38p +1.37%Triad Group (TRD) 31.50p +0.80%Gresham Computing (GHT) 110.50p +0.45%Skyepharma (SKP) 337.25p +0.30% FTSE TechMARK - FallersSarossa (SARS) 1.82p -4.71%SDL (SDL) 383.75p -4.06%Spirent Communications (SPT) 73.25p -2.98%Oxford Instruments (OXIG) 677.00p -0.73%Innovation Group (TIG) 39.50p -0.63%BATM Advanced Communications Ltd. (BVC) 19.75p -0.63%E2V Technologies (E2V) 235.50p -0.63%XP Power Ltd. (DI) (XPP) 1,505.00p -0.33%Ricardo (RCDO) 902.00p -0.28%KCOM Group (KCOM) 90.75p -0.27%
More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.